Ivabradine, Heart Failure and Chronic Kidney Disease
Nephrology @ Point of Care · 2015
DOI: 10.5301/poc.5000190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology @ Point of Care, 2015. Verfasst von Luca Di Lullo und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially in Western countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients' outcomes and quality of life. The latest clinical trials to evaluate ivabradine's efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.
Zitieren
APA
Lullo, L. D., Bellasi, A., Russo, D., Cozzolino, M., Ronco, C., Santoboni, A., & Barbera, G. (2015). Ivabradine, Heart Failure and Chronic Kidney Disease. Nephrology @ Point of Care. https://doi.org/10.5301/poc.5000190
Vancouver
Lullo LD, Bellasi A, Russo D, Cozzolino M, Ronco C, Santoboni A, et al. Ivabradine, Heart Failure and Chronic Kidney Disease. Nephrology @ Point of Care. 2015. doi:10.5301/poc.5000190
BibTeX
@article{Lullo2015,
author = {Lullo, Luca Di and Bellasi, Antonio and Russo, Domenico and Cozzolino, Mario and Ronco, Claudio and Santoboni, Alberto and Barbera, Giovanni},
title = {Ivabradine, Heart Failure and Chronic Kidney Disease},
journal = {Nephrology @ Point of Care},
year = {2015},
doi = {10.5301/poc.5000190}
}
EUVIMED